CoChat

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

Open access
Paludo, Jonas, Mikhael, Joseph R., LaPlant, Betsy R., Halvorson, Alese E., Kumar, Shaji, Gertz, Morie A., Hayman, Suzanne R., Buadi, Francis K., Dispenzieri, Angela, Lust, John A., Kapoor, Prashant, Leung, Nelson, Russell, Stephen J., Dingli, David, Go, Ronald S., Lin, Yi, Gonsalves, Wilson I., Fonseca, Rafael, Bergsagel, P. Leif, Roy, Vivek, Sher, Taimur, Chanan-Khan, Asher A., Ailawadhi, Sikander, Stewart, A. Keith, Reeder, Craig B., Richardson, Paul G., Rajkumar, S. Vincent, Lacy, Martha Q. · 2017 · Blood
Cited by 78

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Key Points: PVD is an active combination in relapsed lenalidomide-refractory MM patients. PVD with weekly bortezomib offers a simpler, more convenient, and well-tolerated regimen option.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2017-05-782961

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 19

  1. Kyle, 2008, Multiple myeloma, Blood, 111, 2962, 10.1182/blood-2007-10-078022 · DOI · Paper page
  2. Manier, 2012, Bone marrow microenvironment in multiple myeloma progression, 10.1155/2012/157496 · DOI · Paper page
  3. Kumar, 2008, Improved survival in multiple myeloma and the impact of novel therapies, Blood, 111, 2516, 10.1182/blood-2007-10-116129 · DOI · Paper page
  4. Quach, 2010, Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma, Leukemia, 24, 22, 10.1038/leu.2009.236 · DOI · Paper page
  5. Kawano, 2015, Targeting the bone marrow microenvironment in multiple myeloma, Immunol Rev, 263, 160, 10.1111/imr.12233 · DOI · Paper page
  6. Rychack, 2011, Overcoming resistance; the use of pomalidomide and dexamethasone in re-sensitizing lenalidomide-resistant multiple myeloma cells, Haematologica, 96, 126
  7. Richardson, 2012, MM-005: a phase 1, multicenter, open-label, dose-escalation study to determine the maximum tolerated dose for the combination of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma, Blood, 120, 727, 10.1182/blood.V120.21.727.727 · DOI
  8. Palumbo, 2014, Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival, J Clin Oncol, 32, 634, 10.1200/JCO.2013.52.0023 · DOI · Paper page
  9. Kyle, 2009, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma, Leukemia, 23, 3, 10.1038/leu.2008.291 · DOI · Paper page
  10. Rychak, 2016, Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma, Br J Haematol, 172, 889, 10.1111/bjh.13905 · DOI · Paper page
  11. San Miguel, 2013, Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial, Lancet Oncol, 14, 1055, 10.1016/S1470-2045(13)70380-2 · DOI · Paper page
  12. Ocio, 2015, In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone, Leukemia, 29, 705, 10.1038/leu.2014.238 · DOI · Paper page
  13. Richardson, 2014, A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma, Blood, 123, 1461, 10.1182/blood-2013-07-517276 · DOI · Paper page
  14. Durie, 2015, Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777, Blood, 126, 25, 10.1182/blood.V126.23.25.25 · DOI · Paper page
  15. Verma, 2015, Identification of a cereblon-independent protein degradation pathway in residual myeloma cells treated with immunomodulatory drugs, Blood, 126, 913, 10.1182/blood.V126.23.913.913 · doi:10.1182/blood.v126.23.913.913
  16. Shah, 2015, Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma, Blood, 126, 2284, 10.1182/blood-2015-05-643320 · DOI · Paper page
  17. Palumbo, 2016, Daratumumab, bortezomib, and dexamethasone for multiple myeloma, N Engl J Med, 375, 754, 10.1056/NEJMoa1606038 · DOI · Paper page
  18. Reeder, 2010, Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma, Blood, 115, 3416, 10.1182/blood-2010-02-271676 · DOI · Paper page
  19. Leleu, 2013, Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02, Blood, 121, 1968, 10.1182/blood-2012-09-452375 · DOI · Paper page

Cited by

See all 78

Metadata

Authors
Paludo, J., Mikhael, J. R., LaPlant, B. R., Halvorson, A. E., Kumar, S., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dispenzieri, A., Lust, J. A., Kapoor, P., Leung, N., Russell, S. J., Dingli, D., Go, R. S., Lin, Y., Gonsalves, W. I., Fonseca, R., Bergsagel, P. L., Roy, V., Sher, T., Chanan-Khan, A. A., Ailawadhi, S., Stewart, A. K., Reeder, C. B., Richardson, P. G., Rajkumar, S. V., & Lacy, M. Q.
Venue
Blood
Published
2017-09-07
Volume
130
Issue
10
Pages
1198-1204
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2512928744
Cited by
78
References
8
FWCI
7.96
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2017-05-782961
The paper
Paludo, J., Mikhael, J. R., LaPlant, B. R., Halvorson, A. E., Kumar, S., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dispenzieri, A., Lust, J. A., Kapoor, P., Leung, N., Russell, S. J., Dingli, D., Go, R. S., Lin, Y., Gonsalves, W. I., Fonseca, R., Bergsagel, P. L., . . . Lacy, M. Q. (2017). Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. https://doi.org/10.1182/blood-2017-05-782961

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.